Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]ABSK011 Mass Balance Study in Healthy Chinese Males
NCT06896760Phase 1Not yet recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irpagratinib in hepatocellular carcinoma (HCC), sponsored by Abbisko Therapeutics. Primary endpoints: Cumulative excretion rate of radioactivity in excreta (urine, feces) and total radioactivity, Percentage of each metabolite in urine and feces relative to administered dose or plasma relative to total exposure AUC and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
irpagratinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06896760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06896760.